Shares of Aldeyra Therapeutics (NASDAQ:ALDX) surged ~26% on Thursday after the company said its lead asset, reproxalap ophthalmic solution, reached the main goal in a Phase 3 trial for patients with ...
Source LinkShares of Aldeyra Therapeutics (NASDAQ:ALDX) surged ~26% on Thursday after the company said its lead asset, reproxalap ophthalmic solution, reached the main goal in a Phase 3 trial for patients with ...
Source Link
Comments